Related Experiment Video

Updated: Jun 24, 2026

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients

Edith L Pfister1, Lori Kennington, Juerg Straubhaar

  • 1Department of Medicine, Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, MA 01655, USA.

Current Biology : CB
|April 14, 2009
PubMed

Insights

Huntington's disease (HD) is a fatal neurodegenerative disorder. This study identifies single-nucleotide polymorphisms (SNPs) to develop allele-specific small interfering RNAs (siRNAs) for targeted Huntington's disease therapy.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Huntington's disease (HD) is a fatal neurodegenerative disorder caused by CAG repeat expansion in the Huntingtin gene, leading to toxic protein formation.
  • Current small interfering RNA (siRNA) strategies struggle to differentiate between normal and mutant Huntingtin alleles.
  • Targeting heterozygous single-nucleotide polymorphisms (SNPs) in the Huntingtin gene offers a potential therapeutic strategy.

Purpose of the Study:

  • To identify heterozygous single-nucleotide polymorphisms (SNPs) in the Huntingtin gene for allele-specific RNA interference (RNAi) therapy in Huntington's disease (HD).
  • To determine the frequency of informative SNPs in HD patient populations.
  • To design and validate allele-specific siRNAs targeting these SNPs.

Main Methods:

  • Sequencing of 22 predicted SNP sites in 225 human samples (HD patients and controls).
  • Genotyping analysis to identify heterozygous SNP sites.
  • Design and validation of allele-specific siRNAs targeting identified SNPs.

Main Results:

  • 48% of the HD patient population was heterozygous at a specific SNP site, with one isoform linked to HD.
  • Several other SNP sites were frequently heterozygous.
  • Five allele-specific siRNAs, targeting three distinct SNP sites, could potentially treat three-quarters of US and European HD patients.

Conclusions:

  • Identification of frequently heterozygous SNPs provides a foundation for allele-specific RNAi therapy for Huntington's disease.
  • Validated allele-specific siRNAs demonstrate the feasibility of this targeted therapeutic approach.
  • This strategy holds promise for treating a significant portion of the HD patient population.

More Related Videos

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy11:22

Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy

Published on: June 27, 2018

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...